Skip to main content

Advertisement

Table 6 Frequency of grade 3–4 adverse events in the FEC and PE arms

From: Weekly taxane–anthracycline combination regimen versus tri-weekly anthracycline-based regimen for the treatment of locally advanced breast cancer: a randomized controlled trial

Adverse event FEC arm [cases (%)] PE arm [cases (%)] P value
Hematologic
 Neutropenia 9 (5.96) 17 (11.97) 0.031
 Anemia 6 (4.00) 10 (7.04) 0.248
 Thrombocytopenia 5 (3.31) 7 (4.93) 0.485
Non-hematologic
 Nausea 4 (2.64) 4 (2.82) 0.458
 Vomiting 2 (1.32) 3 (2.11) 0.603
 Diarrhea 2 (1.32) 4 (2.82) 0.951
 Constipation 3 (1.99) 4 (2.82) 0.267
 Hair loss 24 (15.79) 28 (19.72) 0.583
 Dermatitis 8 (5.30) 11 (7.75) 0.395
 Febrile 1 (0.66) 1 (0.70) 0.965
 Fatigue 7 (4.64) 10 (7.04) 0.379
 Hand-foot syndrome 6 (3.97) 5 (3.52) 0.913
 Allergy 0 (0.00) 1 (0.70) 0.143
  1. FEC tri-weekly 5-fluorouracil–epirubicin–cyclophosphamide regimen, PE weekly paclitaxel–epirubicin regimen